Literature DB >> 24533824

Differential impact of the bisphosphonate alendronate on undifferentiated and terminally differentiated human myogenic cells.

Kosuke Shiomi1, Yuki Nagata, Tohru Kiyono, Atsushi Harada, Naohiro Hashimoto.   

Abstract

OBJECTIVES: Alendronate, a nitrogen-containing bisphosphonate, is well established as a treatment for osteoporosis through regulation of osteoclast activity. Previously, the pharmacological effects of bisphosphonates on cells outside the bone environment have been considered irrelevant because of the bone-targeting property of bisphosphonates. However, the chronic effects of bisphosphonates on tissue-neighbouring bone, in particular skeletal muscles, should not be ignored because patients are treated with bisphosphonates for long periods.
METHODS: Here, we show that the impact of alendronate on immortalized human myogenic cells depends on growth and differentiation-inducing conditions. KEY
FINDINGS: Alendronate disrupted cytoskeletal structures and prevented migration, proliferation and differentiation of undifferentiated human myogenic cells that are involved in muscle regeneration. In contrast, alendronate did not affect the morphology, gene expression or survival of terminally differentiated human myotubes.
CONCLUSIONS: The present results suggest that the muscle regeneration capacity of osteoporosis patients treated with bisphosphonates for long periods may be attenuated. The present research on the pharmacological effects of alendronate on cultured human myogenic cells will contribute to improvement of therapeutic strategies and optimization of rehabilitation programmes for locomotive activity in osteoporosis patients treated with bisphosphonates.
© 2013 Royal Pharmaceutical Society.

Entities:  

Keywords:  bioassay approaches; drug characterization studies; molecular and clinical pharmacology; pharmaceutical analysis; tissue and cellular pharmacology

Mesh:

Substances:

Year:  2013        PMID: 24533824     DOI: 10.1111/jphp.12171

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  The effects of bisphosphonates on osteonecrosis of jaw bone: a stem cell perspective.

Authors:  Hüseyin Abdik; Ezgi Avşar Abdik; Selami Demirci; Ayşegül Doğan; Duygu Turan; Fikrettin Şahin
Journal:  Mol Biol Rep       Date:  2018-12-01       Impact factor: 2.316

2.  Radiographic evidence of treatment with bisphosphonates.

Authors:  M L T Thayer
Journal:  Br Dent J       Date:  2017-04-07       Impact factor: 1.626

3.  Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis.

Authors:  Rahel Meinen; Inna Galli-Lysak; Peter M Villiger; Daniel Aeberli
Journal:  BMC Musculoskelet Disord       Date:  2016-08-05       Impact factor: 2.362

4.  Reversible differentiation of immortalized human bladder smooth muscle cells accompanied by actin bundle reorganization.

Authors:  Naohiro Hashimoto; Tohru Kiyono; Fumihito Saitow; Minoru Asada; Masaki Yoshida
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

5.  Impairment of cold injury-induced muscle regeneration in mice receiving a combination of bone fracture and alendronate treatment.

Authors:  Shigeo Kawada; Atsushi Harada; Naohiro Hashimoto
Journal:  PLoS One       Date:  2017-07-17       Impact factor: 3.240

6.  Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation.

Authors:  Hsien-Chun Chiu; Chen-Yuan Chiu; Rong-Sen Yang; Ding-Cheng Chan; Shing-Hwa Liu; Chih-Kang Chiang
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-03-06       Impact factor: 12.910

7.  The effects of minodronate and activated vitamin D on bone mineral density and muscle mass in postmenopausal women with osteoporosis.

Authors:  Kazuki Fujimoto; Kazuhide Inage; Toru Toyoguchi; Yawara Eguchi; Sumihisa Orita; Kazuyo Yamauchi; Miyako Suzuki; Gou Kubota; Takeshi Sainoh; Jun Sato; Yasuhiro Shiga; Koki Abe; Hirohito Kanamoto; Masahiro Inoue; Hideyuki Kinoshita; Masaki Norimoto; Tomotaka Umimura; Masao Koda; Takeo Furuya; Junichi Nakamura; Tsutomu Akazawa; Atsushi Terakado; Kazuhisa Takahashi; Seiji Ohtori
Journal:  Spine Surg Relat Res       Date:  2018-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.